Literature DB >> 23134386

The promise of antibody-drug conjugates.

Beverly A Teicher, James H Doroshow.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 23134386     DOI: 10.1056/NEJMe1211736

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.

Authors:  Kalli C Catcott; Molly A McShea; Carl Uli Bialucha; Kathy L Miller; Stuart W Hicks; Parmita Saxena; Thomas G Gesner; Mikias Woldegiorgis; Megan E Lewis; Chen Bai; Michael S Fleming; Seth A Ettenberg; Hans K Erickson; Nicholas C Yoder
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

Review 2.  From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?

Authors:  Victoria Shang Wu; Noriko Kanaya; Chiao Lo; Joanne Mortimer; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-18       Impact factor: 4.292

3.  A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.

Authors:  Andrea E Prota; Katja Bargsten; J Fernando Diaz; May Marsh; Carmen Cuevas; Marc Liniger; Christian Neuhaus; Jose M Andreu; Karl-Heinz Altmann; Michel O Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

4.  Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology.

Authors:  Jared Weddell; Manoj S Chiney; Sumit Bhatnagar; John P Gibbs; Mohamad Shebley
Journal:  Clin Transl Sci       Date:  2020-10-19       Impact factor: 4.689

5.  Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Anderson Frank; David Worthylake; Hye-Kyung Chung; Patricia Polacino; Dean H Hamer; Cody P Coyne; Michael G Rosenblum; John W Marks; Gang Chen; Deborah Weiss; Victor Ghetie; Ellen S Vitetta; James E Robinson; Shiu-Lok Hu
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

Review 6.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

7.  Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.

Authors:  Son N Nguyen; Cedric E Bobst; Igor A Kaltashov
Journal:  Mol Pharm       Date:  2013-04-10       Impact factor: 4.939

Review 8.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

9.  Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids.

Authors:  Nicolas Boyer; Karen C Morrison; Justin Kim; Paul J Hergenrother; Mohammad Movassaghi
Journal:  Chem Sci       Date:  2013-04-01       Impact factor: 9.825

Review 10.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.